Amongst patents with IDH1- or IDH2-mutant glioma, the therapy mixture of Voranigo (vorasidenib) plus Temodar (temozolomide) didn’t result in any critical negative effects or dose-limiting toxicities (DLTs), scientific trial outcomes have proven.
Information from the section 1b IDHEAL-4U trial have been introduced on the 2025 Society for Neuro-Oncology Annual Assembly.
Findings demonstrated that, with a median therapy length 5.5 months, all sufferers (seven sufferers) skilled any-grade treatment-emergent negative effects; 28.6% (two sufferers) had grade 3 (extreme) or greater treatment-emergent negative effects, which included decreased neutrophil rely (14.3%) and decreased platelet rely (28.6%). No sufferers discontinued therapy as a result of treatment-emergent negative effects, and all sufferers accomplished the DLT analysis portion of the research. As of the Sept. 8, 2025, knowledge cutoff, 85.7% (six sufferers) remained on therapy with each research medicine.
Glossary
Elevated alanine aminotransferase (ALT) ranges: ALT is an enzyme discovered principally within the liver. When ALT ranges are greater than regular on a blood check, it may be an indication that the liver is irritated or broken.
Karnofsky efficiency standing
The Karnofsky efficiency standing is a rating docs use to explain how effectively an individual with most cancers is ready to perform each day actions. The size goes from 0 to 100. A better quantity means the particular person is extra energetic and capable of take care of themselves; a decrease quantity means they want extra assist.
Remedy-emergent negative effects led to dose reductions in 42.9% of sufferers; notably, 14.3% required dose reductions of solely Voranigo, 28.6% wanted dose reductions of solely Temodar, and no sufferers required dose reductions of each brokers. Dose reductions of Voranigo stemmed from elevated alanine aminotransferase (ALT) ranges (14.3%), and reductions of Temodar have been as a result of decreased platelet rely (28.6%) and decreased neutrophil rely (14.3%).
Remedy-emergent negative effects required research drug interruption in 57.1% of sufferers, together with 28.6% who wanted dose interruptions of each therapies, which was as a result of elevated ALT ranges (28.6%). Solely Voranigo was interrupted in 14.3% of sufferers, and solely Temodar was interrupted in 57.1% of sufferers. Remedy-emergent negative effects resulting in dose interruptions of solely Voranigo included elevated ALT ranges (14.3%), and these included neutropenia (42.9%) and decreased platelet rely (42.9%) for Temodar solely.
“Based mostly on knowledge from the Might 6, 2025, knowledge cutoff, the security evaluate committee declared [Voranigo at] 40 mg because the advisable mixture dose [RCD] to be given together with standard-of-care [Temodar],” lead research writer Dr. Macarena de la Fuente and colleagues wrote in a poster presentation of the information.
de la Fuente is an affiliate professor of neuro-oncology, chief of the Neuro-Oncology Division, scientific service chief for Neuro-Oncology Service Line – Sylvester Complete Most cancers Middle, chair of the Neuro-Oncology Web site Illness Group, director of the Neuro-Oncology Fellowship Program, and oncology scientific service chief for Neuro-Oncology on the Miller Faculty of Drugs of College of Miami in Florida.
Why are Voranigo and Temodar being evaluated as a mix technique in IDH1/2-mutated glioma?
Though Voranigo is accepted by the FDA for the therapy of grownup and pediatric sufferers 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with a prone IDH1 or IDH2 mutation, as detected by an FDA-approved check, following surgical procedure together with biopsy, sub-total resection, or gross whole resection, therapy with IDH inhibitor monotherapy is unlikely to result in illness management in sufferers with higher-grade, extra aggressive gliomas.
As such, de la Fuente and colleagues hypothesized that including Voranigo to Temodar might, “exploit the molecular vulnerabilities of higher-grade [IDH1/2-mutant] gliomas whereas controlling extra quickly proliferative tumor cells.”
IDHEAL-4U is a multicenter section 1b/2 trial designed to judge the mixture, with section 1b specializing in security, and the continued section 2 portion taking a look at preliminary efficacy, security, and tolerability for the RCD in sufferers with grade 4 astrocytoma harboring IDH1/2 mutations.
In section 1b, investigators enrolled sufferers a minimum of 12 years of age with grade 2 to 4 gliomas with IDH1/2 mutations who have been eligible for Temodar within the adjuvant setting after radiotherapy or at first illness recurrence.
Voranigo was first evaluated at 40 mg as soon as per day together with Temodar at 150 mg/m2 in cycle 1, then 200 mg/m2 in cycles 2 to 12. Voranigo was continued till illness development. After security evaluate committee enter and evaluation of DLT charge and BOIN design, investigators might dose de-escalate to judge Voranigo to twenty mg per day, or declare the RCD.
What have been the affected person traits in section 1b?
The seven enrolled sufferers had a median age of 36 years, and 57.1% have been feminine. Karnofsky efficiency standing at baseline included 100 (14.3%), 90 (57.1%), 80 (14.3%) and 70 (14.3%). Affected person tumor sorts included frontline grade 3 astrocytoma (42.9%), frontline grade 4 astrocytoma (14.3%), recurrent grade 4 astrocytoma (14.3%), frontline grade 3 oligodendroglioma (14.3%) and recurrent grade 4 oligodendroglioma (14.3%).
All sufferers had acquired prior radiation remedy. Three sufferers (42.9%) acquired prior systemic remedy, which was completely Temodar.
Reference
- “Section 1b security outcomes of vorasidenib together with temozolomide in sufferers with mutant IDH1 or IDH2 glioma” by Dr. Macarena de la Fuente et al., introduced at: 2025 SNO Annual Assembly; November 19-23, 2025; Honolulu, HI. Summary CTNI-34.
For extra information on most cancers updates, analysis and schooling,
